DNA vaccine shows promise against anal precancer in HIV patients
NCT ID NCT03603808
First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times
Summary
This study tested a DNA-based vaccine called VGX-3100 in 44 HIV-positive adults with high-grade anal precancer caused by HPV types 16 or 18. The vaccine was given with a mild electric pulse (electroporation) to help cells absorb it and boost the immune system's attack on the abnormal cells. The main goal was to see if the lesions shrank or disappeared within 48 weeks. The approach aims to control the disease and prevent progression to cancer, but does not eliminate the need for ongoing HIV management.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAL HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Anal Dysplasia Clinic MidWest
Chicago, Illinois, 60614, United States
-
Boston Medical Center
Boston, Massachusetts, 02118, United States
-
Grady Health System
Atlanta, Georgia, 30303, United States
-
Laser Surgery Care
New York, New York, 10011, United States
-
Montefiore Medical Center
The Bronx, New York, 10461, United States
-
University of California, San Francisco
San Francisco, California, 94143, United States
-
University of Puerto Rico
San Juan, 00936-3027, Puerto Rico
-
Wake Forest Baptist health Sciences
Winston-Salem, North Carolina, 27157, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.